These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 24594235)

  • 1. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-translational modifications talk and crosstalk to class IIa histone deacetylases.
    Guttzeit S; Backs J
    J Mol Cell Cardiol; 2022 Jan; 162():53-61. PubMed ID: 34416247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.
    Zhou B; Margariti A; Zeng L; Xu Q
    Cardiovasc Res; 2011 Jun; 90(3):413-20. PubMed ID: 21233251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
    Abend A; Kehat I
    Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biology and therapeutic implications of HDACs in the heart.
    McKinsey TA
    Handb Exp Pharmacol; 2011; 206():57-78. PubMed ID: 21879446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms.
    Weeks KL; Avkiran M
    J Physiol; 2015 Apr; 593(8):1785-97. PubMed ID: 25362149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
    Kee HJ; Kook H
    J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy.
    Eom GH; Kook H
    BMB Rep; 2015 Mar; 48(3):131-8. PubMed ID: 25388210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart.
    Habibian J; Ferguson BS
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
    Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
    Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease.
    Li P; Ge J; Li H
    Nat Rev Cardiol; 2020 Feb; 17(2):96-115. PubMed ID: 31350538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11.
    Madsen AS; Kristensen HM; Lanz G; Olsen CA
    ChemMedChem; 2014 Mar; 9(3):614-26. PubMed ID: 24375963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease.
    Wright LH; Menick DR
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H199-206. PubMed ID: 27208161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
    Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
    Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
    Koppel I; Timmusk T
    Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation.
    Lkhagva B; Kao YH; Chen YC; Chao TF; Chen SA; Chen YJ
    Eur J Pharmacol; 2016 Jun; 781():250-7. PubMed ID: 27089819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment.
    Colussi C; Illi B; Rosati J; Spallotta F; Farsetti A; Grasselli A; Mai A; Capogrossi MC; Gaetano C
    Pharmacol Res; 2010 Jul; 62(1):3-10. PubMed ID: 20227503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylases--an important class of cellular regulators with a variety of functions.
    Hildmann C; Riester D; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.